Key takeaways
Tremfya (guselkumab) and Cosentyx (secukinumab) are both monoclonal antibodies used to treat inflammatory conditions, but they work differently. Tremfya targets interleukin-23 (IL-23) and is used for moderate-to-severe plaque psoriasis and active psoriatic arthritis. Cosentyx, on the other hand, targets interleukin-17 (IL-17) and treats a wider range of conditions, including plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa. Tremfya is injected under the skin every 8 weeks after initial doses, while Cosentyx is aslo an injection under the skin but is typically injected monthly. Cosentyx can also be given as an IV infusion for certain conditions. Both medications can raise the risk of infections, but Cosentyx may also worsen inflammatory bowel disease symptoms.
